Dermasol-N® is indicated inShort
courses treatment of recalcitrant eczemas
Psoriasis (excluding widespread plaque psoriasis) where secondary bacterial infection or fungal infection is present,suspected or likely to occur.
Other inflammatory conditions which do not respond satisfactorily to less active steroids.
DOSAGE AND ADMINISTRATION
Adults: Apply sparingly to the affected area once or twice daily until improvement occurs. In very resistant lesion, specially where there is hyperkeratosis,
the anti-inflammatory effect of Dermasol-N® can be enhanced (if necessary) by occluding the treatment area with polythene. Treatment should not be
continued for more than 7 days without medical supervision. If a longer course is necessary, it is recommended that treatment should not be continued for
more than 4 weeks without the patient’s condition being reviewed.
Elderly: Dermasol-N® is suitable for use in elderly. Caution should be exercised in cases where a decrease in renal function exists and significant systemic
absorption of Neomycin Sulphate may occur.
Children:Dermasol-N® is suitable for use in children (2 years and over) at the same dose as adults.A possibility of increased absorption exists in very young
children,thus Dermasol-N® is not recommended for use in neonates and infants (younger than 2 years).
This medication is contraindicated in rosacea, acne vulgaris and perioral dermatitis, primary cutaneous viral infection (eg-Herpes simplex, chicken pox) and
hypersensitivity to the preparation.
Long-term continuous topical therapy should be avoided where possible, particularly in infants and children, as adrenal suppression can occur readily even
without occlusion. If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye, as glaucoma might result. If this
medication does enter the eye,the affected eye should be thoroughly washed with copious amount of water.
USE IN PREGNANCY AND LACTATION
There is little information to demonstrate the possible effect of topically applied Neomycin in pregnancy and lactation. However, Neomycin present in the
maternal blood can cross the placenta and may give rise to a theoretical risk of foetal toxicity, thus the use of the preparation is not recommended in
pregnancy and lactation.
The safety of Clobetasol Propionate has not been established in lactating mothers.
As with other topical corticosteroids, prolonged use of large amount or treatment of extensive areas can result in sufficient systemic absorption to produce
the features of hypercortisolism. The effect is more likely to occur in infants and children and if occlusive dressings are used. Prolonged and intensive
treatment with highly active corticosteroid preparations may cause local atrophic changes in the skin such as thinning, striae, and dilatation of the
superficial blood vessels, particularly when occlusive dressings are used, or when skin folds are involved. There are reports of pigmentation changes and
hypertrichosis with topical steroids.
Neomycin Sulphate can intensify and prolong the respiratory depressant effects of neuromuscular blocking agents following significant systemic
absorption. However, if used in accordance with the recommendations, systemic exposure to Neomycin Sulphate is expected to be minimal and drug
interactions are unlikely to be significant.No hazardous interactions have been reported with use of Clobetasol Propionate or Nystatin